TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12796572

Group type: EXPERIMENTAL
Intervention: ECMO for neonates with meconium aspiration syndrome
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: ECMO after heart, lung, heart-lung, and liver transplant
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: ECMO for severe asthma
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: ECMO for hydrocarbon aspiration
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: ECMO for congestive heart failure due to cerebral arteriovenous malformation
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: ECMO for tracheal occlusion during endoscopic stent manipulation
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: ECMO for meningitis
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: ECMO for viral pneumonia
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Overall ECMO program
Number of subjects: 216
Study: 10321421

Group type: EXPERIMENTAL
Intervention: Insulin lispro Mix50 (50% insulin lispro/50% NPL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Insulin lispro Mix25 (25% insulin lispro/75% NPL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Human insulin 50/50 (50% regular insulin/50% NPH insulin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Human insulin 30/70 (30% regular insulin/70% NPH)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Insulin lispro mixtures
Number of subjects: 100
Study: 8921782

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol (milligrams per 1000 kilocalories)
Number of subjects: 11342

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (percent of kilocalories)
Number of subjects: 11342

Group type: EXPERIMENTAL
Intervention: Starch (percent of kilocalories)
Number of subjects: 11342

Group type: EXPERIMENTAL
Intervention: Protein
Number of subjects: 11342

Group type: EXPERIMENTAL
Intervention: Ratio of dietary polyunsaturated to saturated fatty acids
Number of subjects: 11342

Group type: EXPERIMENTAL
Intervention: Body mass, dietary sodium and ratio of sodium to potassium, and alcohol intake
Number of subjects: 11342

Group type: EXPERIMENTAL
Intervention: Intake of potassium and caffeine
Number of subjects: 11342
Study: 1872515

Group type: EXPERIMENTAL
Intervention: Zinc sulfate as sustained-release tablets of 22 mg Zn++ (Zinklet), administered three times daily for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 6820504

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg three times per day
Number of subjects: 9
Study: 31444815

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-MY20 Disease Symptoms (DS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-MY20 Side Effects of Treatment (SE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-MY20 Body Image (BI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-MY20 Future Perspective (FP)
Number of subjects: 0
Study: 27696727

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol treatment for axial SpA
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol treatment for PsA
Number of subjects: 47
Study: 26139231

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 30
Study: 23788270

Group type: EXPERIMENTAL
Intervention: Bevacizumab with irinotecan or temozolomide after 2 chemotherapy cycles (8 weeks)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Bevacizumab with irinotecan or temozolomide after 4 chemotherapy cycles (16 weeks)
Number of subjects: 123
Study: 21782519

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E) 0, 1, 2 month schedule
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E) 0, 1, 7 month schedule
Number of subjects: 511

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 511
Study: 19674936

Group type: EXPERIMENTAL
Intervention: Sodium clodronate (2080 mg, four tablets per day) for up to 3 years (metastatic disease) or 5 years (non-metastatic)
Number of subjects: 819

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 819
Study: 17514693

Group type: EXPERIMENTAL
Intervention: Early open surgical repair
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1090
Study: 15352908

Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 71

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 71
Study: 12161007

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) administered intravenously at a dose of 2.5 IU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle administration (control)
Number of subjects: 0
Study: 9617509

Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Haloperidol 10 mg daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lithium 800 to 1200 mg daily
Number of subjects: 45
Study: 7654645

Group type: EXPERIMENTAL
Intervention: Perineoplasty
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vestibuloplasty
Number of subjects: 21
Study: 1812444

Group type: EXPERIMENTAL
Intervention: Test packs (nylon sleeves)
Number of subjects: 7200

Group type: COMPARATOR
Intervention: Control packs (nylon sleeves)
Number of subjects: 7200

Group type: EXPERIMENTAL
Intervention: Test packs (paper envelopes)
Number of subjects: 7200

Group type: COMPARATOR
Intervention: Control packs (paper envelopes)
Number of subjects: 7200

Group type: EXPERIMENTAL
Intervention: Test packs (peel pouches)
Number of subjects: 7200

Group type: COMPARATOR
Intervention: Control packs (peel pouches)
Number of subjects: 7200
Study: 7018166

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2-tablets (0.5-1.5 mg/hr)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Intravenous oxytocin (7.5-45 mIU/min)
Number of subjects: 201
Study: 30167831

Group type: EXPERIMENTAL
Intervention: Artificial hydronephrosis (group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No hydronephrosis (group B)
Number of subjects: 300
Study: 28120350

Group type: EXPERIMENTAL
Intervention: Rhealba® Oat Extract-based emollient applied once or twice daily during a 2-week treatment phase
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rhealba® Oat Extract-based emollient
Number of subjects: 30
Study: 26468934

Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 376

Group type: COMPARATOR
Intervention: PGE2 (dinoprostone insert)
Number of subjects: 376
Study: 24499078

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS), Group A: n = 35
Number of subjects: 72

Group type: COMPARATOR
Intervention: PAD drugs (cilostazol or sarpogrelate), Group B: n = 37
Number of subjects: 72
Study: 21951464

Group type: EXPERIMENTAL
Intervention: Mandibular implant overdentures (IODs)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Complete dentures (CDs)
Number of subjects: 255
Study: 18977113

Group type: EXPERIMENTAL
Intervention: Information + self‐regulation intervention
Number of subjects: 256

Group type: COMPARATOR
Intervention: Information intervention
Number of subjects: 256
Study: 17516958

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (150 g tablet, containing 50 mg of elemental iron) daily throughout pregnancy (n = 370)
Number of subjects: 727

Group type: COMPARATOR
Intervention: Placebo daily throughout pregnancy (n = 357)
Number of subjects: 727
Study: 15702062

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.0134% in 10 ml intrathecal volume for spontaneous labor
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.0195% in 10 ml intrathecal volume for induced labor
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (general outcome)
Number of subjects: 75
Study: 11270910

Group type: EXPERIMENTAL
Intervention: Sertraline (200 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9673725

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 46

Group type: COMPARATOR
Intervention: No anaesthesia
Number of subjects: 46
Study: 8011502

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g/day of concentrated n-3 fatty acids)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Corn oil (isoenergetic amount)
Number of subjects: 145
Study: 2685677

Group type: EXPERIMENTAL
Intervention: Preterm Labor Detection Clinic Program
Number of subjects: 943

Group type: COMPARATOR
Intervention: High-risk controls
Number of subjects: 943

Group type: COMPARATOR
Intervention: Low-risk controls
Number of subjects: 943
Study: 322520

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of hydroxychloroquine and aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31718229

Group type: EXPERIMENTAL
Intervention: Self-administered acupressure (n=17, two training sessions followed by self-practice for 6 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Knee health education (n=18, two health education sessions about KOA management followed by self-care for 6 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Self-administered acupressure
Number of subjects: 35

Group type: COMPARATOR
Intervention: Knee health education
Number of subjects: 35
Study: 31775798

Group type: EXPERIMENTAL
Intervention: Condition B - Reduced slots for less-healthy drinks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Condition A - Standardised levels of healthier products
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Condition C - Increased slots for healthier products
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Condition D - Reduced slots for healthier snacks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Condition E - Increased slots for less-healthy products
Number of subjects: 10
Study: 28760194

Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty (UPPP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified Radiofrequency Tissue Ablation (MRFTA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: MRFTA
Number of subjects: 40

Group type: COMPARATOR
Intervention: UPPP
Number of subjects: 40
Study: 25858205

Group type: EXPERIMENTAL
Intervention: Tobacco Tactics program
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control hospital
Number of subjects: 2
Study: 23868428

Group type: EXPERIMENTAL
Intervention: Endoscopic partial arytenoidectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Endoscopic total arytenoidectomy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endoscopic total and partial arytenoidectomy
Number of subjects: 20
Study: 19604587

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy (including fibrinolysis and primary PCI)
Number of subjects: 5867

Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 5867

Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 5867

Group type: COMPARATOR
Intervention: No early reperfusion therapy
Number of subjects: 5867
Study: 20196389

Group type: EXPERIMENTAL
Intervention: Early surfactant administration (2 hours after the first dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Late surfactant administration (6 hours after the first dose)
Number of subjects: 40
Study: 16769945

Group type: EXPERIMENTAL
Intervention: Friedreich Ataxia Rating Scale (FARS)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Performance measures (9‐hole peg test, timed 25‐foot walk, PATA test, low‐contrast letter acuity)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Composite measures created using cohort means and standard deviations
Number of subjects: 155
Study: 15050490

Group type: EXPERIMENTAL
Intervention: Myocardial velocity profile (MVP) using color‐coded tissue Doppler imaging (TDI) in patients with cardiac amyloidosis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (clinically normal controls)
Number of subjects: 80
Study: 11734414

Group type: EXPERIMENTAL
Intervention: Limb starting position visible during prism exposure
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Visual feedback available early or late in target pointing movements
Number of subjects: 56

Group type: COMPARATOR
Intervention: Limb starting position not visible during prism exposure
Number of subjects: 56

Group type: COMPARATOR
Intervention: Visual feedback not available
Number of subjects: 56
Study: 9408721

Group type: EXPERIMENTAL
Intervention: Meta-analysis of randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis of small trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large trials
Number of subjects: 0
Study: 8387085

Group type: EXPERIMENTAL
Intervention: lacto-ovovegetarian diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: omnivorous diet
Number of subjects: 21
Study: 3120571

Group type: EXPERIMENTAL
Intervention: Lacto-ovovegetarian diet (L)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vegan diet (V)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mixed diet (M)
Number of subjects: 12
Study: 30547749

Group type: COMPARATOR
Intervention: Repellent (N,N‐diethyl‐benzamide - 12% w/w, cream) distributed by Village Health Volunteers (VHVs) during the malaria transmission season.
Number of subjects: 0
Study: 26485693

Group type: EXPERIMENTAL
Intervention: v-CPR
Number of subjects: 180

Group type: COMPARATOR
Intervention: t-CPR
Number of subjects: 180
Study: 25042931

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22838228

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calcium Hydroxide
Number of subjects: 30
Study: 20510211

Group type: EXPERIMENTAL
Intervention: High bolus dose tirofiban
Number of subjects: 1398

Group type: COMPARATOR
Intervention: No tirofiban (phase 1) or placebo (phase 2)
Number of subjects: 1398
Study: 19835025

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 71
Study: 17064548

Group type: EXPERIMENTAL
Intervention: Music group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 12812864

Group type: EXPERIMENTAL
Intervention: 500 mg/day methylprednisolone given IV for 5 days, then PO taper down
Number of subjects: 9

Group type: COMPARATOR
Intervention: Healthy female controls
Number of subjects: 9
Study: 10754621

Group type: EXPERIMENTAL
Intervention: Undiluted propofol infusion at rates of 10, 15, 20, 30, 40, 60, 100, 200, and 300 mg/kg‐1/h‐1
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Diluted propofol (0.5 mg/ml) infusion at rates of 10, 15, 30, 60, 100, 200, and 300 mg/kg‐1/h‐1
Number of subjects: 250

Group type: COMPARATOR
Intervention: Crystalloid infusion at the same rates as group C
Number of subjects: 250
Study: 8796792

Group type: EXPERIMENTAL
Intervention: 0.125 mg/2 ml PGE2 gel
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 0.25 mg/2 ml PGE2 gel
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 0.5 mg/2 ml PGE2 gel
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 229
Study: 1639464

Group type: EXPERIMENTAL
Intervention: 1 ml/kg ethanol (vodka)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonalcoholic beverage
Number of subjects: 16
Study: 6539613

Group type: EXPERIMENTAL
Intervention: Gastric juice-resistant formulation of cyclophosphamide (CP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rapid release formulation 1 of cyclophosphamide (CP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rapid release formulation 2 of cyclophosphamide (CP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous application of cyclophosphamide (CP)
Number of subjects: 12
Study: 30653342

Group type: EXPERIMENTAL
Intervention: HIIT-2 (10 × 60 s cycling, ∼83% peak power output, 2 times per week for 8 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: HIIT-3 (10 × 60 s cycling, ∼83% peak power output, 3 times per week for 8 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 35
Study: 30838824

Group type: EXPERIMENTAL
Intervention: Noble metal coated CVC
Number of subjects: 45

Group type: COMPARATOR
Intervention: Uncoated CVC
Number of subjects: 45
Study: 26335243

Group type: EXPERIMENTAL
Intervention: Preoperative clinical diagnosis based on computed tomography or magnetic resonance imaging
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Preoperative clinical diagnosis
Number of subjects: 166
Study: 24971786

Group type: EXPERIMENTAL
Intervention: Menopausal gonadotropins
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (multivitamin)
Number of subjects: 78
Study: 22768793

Group type: EXPERIMENTAL
Intervention: IVR intervention (IVR screening plus automated questions to identify barriers and offer transfer to QL)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Control group (IVR screening for current smoking without intervention)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: IVR intervention
Number of subjects: 521
Study: 21058209

Group type: EXPERIMENTAL
Intervention: Walking exercise program with ankle weights
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study: 18339108

Group type: EXPERIMENTAL
Intervention: MET/CBT coping skills training
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Contingency management (ContM)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: MET/CBT + ContM
Number of subjects: 240

Group type: COMPARATOR
Intervention: Case management control condition
Number of subjects: 240
Study: 15765254

Group type: EXPERIMENTAL
Intervention: Climodien (estradiol valerate 2 mg and dienogest 3 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Estradiol valerate (EV) 2 mg alone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 12081158

Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10572334

Group type: EXPERIMENTAL
Intervention: Citalopram plus clomipramine (n = 9)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Citalopram alone (n = 7)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Citalopram (n = 6) for patients who did not tolerate fluoxetine or clomipramine alone
Number of subjects: 16
Study: 7603935

Group type: EXPERIMENTAL
Intervention: Treatment group (booklet with adjunct questions)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Treatment control group (booklet without adjunct questions)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-treatment control group
Number of subjects: 90
Study: 2196621

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 830372

Group type: EXPERIMENTAL
Intervention: Bacterial endotoxin (5 ng/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Etiocholanolone (0.3 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (propylene glycol)
Number of subjects: 18
Study: 31965432

Group type: EXPERIMENTAL
Intervention: Shikamana intervention (modified Next Step Counseling + peer support)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study: 30289355

Group type: EXPERIMENTAL
Intervention: alemtuzumab 12 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: SC IFNB-1a 44 μg
Number of subjects: 0
Study: 29059133

Group type: EXPERIMENTAL
Intervention: MK-0657 (7 mg)
Number of subjects: 22
Study: 25935606

Group type: EXPERIMENTAL
Intervention: Lateral Collagen Meniscus Implant (CMI)
Number of subjects: 43
Study: 23730996

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 125

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 125
Study: 20177755

Group type: EXPERIMENTAL
Intervention: Daily breastfeeding log for a minimum of 3 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study: 19302077

Group type: EXPERIMENTAL
Intervention: Viscoanaesthesia (VisThesia)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Intracameral lidocaine (0.5 cc of 1% unpreserved lidocaine)
Number of subjects: 98
Study: 17034604

Group type: EXPERIMENTAL
Intervention: Intravesical therapy based on in vitro cytotoxicity assay
Number of subjects: 47

Group type: COMPARATOR
Intervention: Intravesical BCG according to International Protocol (control group)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Single drug regimen
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Double-drug regimen
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: BCG with cytotoxic drugs
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b combinations
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: In vitro group
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 15612142

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 1287

Group type: COMPARATOR
Intervention: Control (untreated infants)
Number of subjects: 1287
Study: 11544459

Group type: EXPERIMENTAL
Intervention: FC1Ps
Number of subjects: 8
Study: 9663175

Group type: EXPERIMENTAL
Intervention: 600 mg rifampin once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40 mg SB 216469 twice a day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 60 mg SB 216469 twice a day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40 mg SB 216469 three times a day
Number of subjects: 60
Study: 7816765

Group type: EXPERIMENTAL
Intervention: Multiple Dose (MD) regimen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single Dose (SD) regimen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Monte Carlo simulations of SD and MD
Number of subjects: 30
Study: 3076707

Group type: EXPERIMENTAL
Intervention: Weekly antimalarial chemoprophylaxis (chloroquine)
Number of subjects: 73
Study: 30939923

Group type: EXPERIMENTAL
Intervention: Financial incentives to increase physical activity
Number of subjects: 0
Study: 27783213

Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (NO)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhaled Epoprostenol Sodium (PGI2)
Number of subjects: 13
Study: 26753485

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intramuscular pethidine
Number of subjects: 80
Study: 23218801

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8